Aminotransferases (Transaminases) Inhibitor

Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities.

Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.

BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC₅₀ of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC₅₀=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.

BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC₅₀s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively. BCATc, also called BCAT1, is in the cytoplasm.

Ligustrazine (Standard) (Chuanxiongzine (Standard)) is the analytical standard of Ligustrazine (HY-N0264). This product is intended for research and analytical applications. Ligustrazine (Chuanxiongzine) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.

α-Glucosidase-IN-119 is an α-glucosidase inhibitor with an IC₅₀ of 3.32 μM and oral effectiveness. α-Glucosidase-IN-119 acts as an antihyperglycemic agent, reduces blood glucose levels, restores normal levels of alkaline phosphatase, aspartate transaminase, alanine transaminase, urea, blood urea nitrogen, and total protein, and exhibits antioxidant activity. α-Glucosidase-IN-119 can be used for the research of type 2 diabetes mellitus.

ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease.

PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC₅₀s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively).

ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC₅₀ of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8⁺ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8⁺ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer.

Ligustrazine hydrochloride (Chuanxiongzine hydrochloride) is an orally active, blood-brain barrier-permeable alkaloid. It can be isolated from Ligusticum striatum DC. Ligustrazine hydrochloride reduces ROS, upregulates the levels of p-Akt/Akt and p-eNOS/eNOS, and decreases ALT and AST. It inhibits glutamate excitotoxicity, calcium overload, oxidative stress, ischemia-reperfusion injury and atherosclerotic plaque progression, enhances synaptic plasticity, and improves neurological function, cerebral infarct volume and brain water content. Ligustrazine hydrochloride possesses anti-inflammatory, antioxidant, lipid-lowering, endothelial protective and hepatoprotective activities. It can be used in studies related to ischemic stroke, cerebral ischemia-reperfusion injury and atherosclerosis.

L-Prolylglycine is a proline-glycine dipeptide. L-Prolylglycine is absorbable through the jejunal and ileal mucosa. In streptozotocin (HY-13753)-induced diabetic mice, L-Prolylglycine reduces hepatic ALT activity and increases hepatic ALP activity. L-Prolylglycine prevents excessive elevation of blood glucose in diabetic mice. L-Prolylglycine is applicable to diabetes-related research.

iGOT1-01 is a potent aspartate aminotransferase 1 (glutamate oxaloacetate transaminase 1; GOT1) inhibitor. iGOT1-01 has IC₅₀s of 85 μM and 11.3 μM in MDH coupled GOT1 enzymatic assay and GOT1/GLOX/HRP assay, respectively. iGOT1-01 has anti-cancer activity.

BCAT-IN-1 is a potent, selective and orally active inhibitor of BCATm, with a pIC₅₀ of 7.3. BCAT-IN-1 shows 100-fold selectivity for BCATm over BCATc (pIC₅₀=5.4). BCAT-IN-1 can be used for the research of metabolic diseases.

BFF-816 is an orally active kynurenine aminotransferase II (KAT II) inhibitor. BFF-816 can be used in the research of the neurobiology of KYNA.

Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt. Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria.

HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).

Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models.

WQQ-345 is an orally active BCAT1 inhibitor with an IC₅₀ values of 10.8 mM. WQQ-345 reduces cellular α-KG levels, upregulating H3K27me3 expression, decreasing glycolytic enzyme expression, and impairing glycolysis activity. WQQ-345 reduces colony formation, suppresses growth of BCAT1-high TKI-resistant lung cancer cells. WQQ-345 exerts in vitro and in vivo antitumor activity. WQQ-345 can be used for the research of TKI-resistant non-small cell lung cancer and TKI-resistant lung cancer.

3HKT-IN-1 (Compound 17122279) is an Anopheles gambiae 3-hydroxykynurenine transaminase (3HKT) inhibitor. 3HKT-IN-1 can be used for Malaria research.

hOAT-IN-1 (compound 5) is a mechanical inhibitor of human ornithine aminotransferase (hOAT). hOAT-IN-1 as a time-dependent inhibitor can form tightly bound PLP inhibitor adduct with hOAT. hOAT-IN-1 can result IN tight occupation of the active site of hOAT. hOAT-IN-1 can be used in the study of lung cell carcinoma .